Last quarter (Q3 2023), Cue Biopharma's total revenue was $2.10M, an increase of 2988.24% from the same quarter last year. In Q3, Cue Biopharma's net income was $-11.01M. See Cue Biopharma’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Dec 19	Dec 18
Total Revenue	$ 3.82M	$ 1.25M	$ 14.94M	$ 3.15M	$ 3.46M	$ 1.14M
Cost of Revenue	-	-	-	-	-	-
Gross Profit	$ 3.82M	$ 1.25M	$ 14.94M	-	-	-
Operating Expense	$ 26.97M	$ -54.75M	$ 58.65M	$ 48.20M	$ 40.23M	$ 39.84M
Operating Income	$ -53.18M	$ -53.50M	$ -43.71M	$ -45.04M	$ -36.77M	$ -38.70M
Net Non Operating Interest Income Expense	$ 2.37M	$ 214.43K	$ 45.90K	$ 463.91K	$ 482.79K	$ 376.01K
Other Income Expense	$ -134.87K	$ -276.63K	$ -7.13K	-	$ 64.08K	$ 165.34K
Pretax Income	$ -51.89M	$ -53.01M	$ -43.67M	$ -44.58M	$ -36.29M	$ -38.16M
Tax Provision	-	-	$ 495.00K	$ 206.25K	$ 412.50K	$ 825.00K
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -51.89M	$ -53.01M	$ -44.16M	$ -44.78M	$ -36.70M	$ -38.98M
Basic EPS	$ -2.00	$ -1.49	$ -1.41	$ -1.56	$ -1.66	$ -1.94
Diluted EPS	$ -1.19	$ -1.49	$ -1.41	$ -1.56	$ -1.66	$ -1.94
Basic Average Shares	$ 171.46M	$ 35.65M	$ 31.29M	$ 28.69M	$ 22.04M	$ 20.13M
Diluted Average Shares	$ 171.46M	$ 35.65M	$ 31.29M	$ 28.69M	$ 22.04M	$ 20.13M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 26.97M	$ 54.47M	$ 58.65M	$ 48.20M	$ 40.23M	$ 39.84M
Net Income From Continuing And Discontinued Operation	$ -51.89M	$ -53.01M	$ -44.16M	$ -44.78M	$ -36.70M	$ -38.98M
Normalized Income	$ -8.69M	$ -41.88M	-	$ -44.78M	$ -36.70M	$ -38.98M
Interest Expense	-	-	-	-	-	-
EBIT	$ -51.98M	$ -52.30M	$ -43.67M	$ -45.04M	$ -36.77M	$ -38.70M
EBITDA	$ -50.86M	$ -50.78M	$ -39.38M	$ -45.04M	$ -35.96M	$ -37.94M

Currency in USD

Cue Biopharma Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing